8-K: Fennec Pharmaceuticals Inks Exclusive Licensing Deal with Norgine for PEDMARQSI in Europe, Australia, and New Zealand

Fennec Pharmaceuticals has granted Norgine exclusive rights to commercialize PEDMARQSI in key international markets, securing a substantial upfront payment and potential future milestones.

Summary

• Fennec Pharmaceuticals has entered into a licensing and supply agreement with Norgine Pharma UK Limited for the commercialization of PEDMARQSI in the European Economic Area, Switzerland, the United Kingdom, Australia, and New Zealand.
• The agreement includes a 40 million upfront payment to Fennec, which was received on March 15, 2024.
• Fennec is also eligible to receive up to 210 million in additional payments upon achieving certain regulatory and commercial milestones.
• Tiered royalty payments based on net sales of PEDMARQSI in the licensed territories will range from the mid-teen to mid-twenty percent.
• These royalty payments are subject to reduction if a generic version of PEDMARQSI becomes available.
• The agreement's term extends until March 15, 2034, or the expiration of regulatory market exclusivity or the last-to-expire patent for PEDMARQSI in each respective country, whichever is longer.
• The agreement will automatically renew for additional three-year periods unless either party provides a one-year notice of non-renewal.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant upfront payment, potential milestone payments, and the partnership with a reputable company. The agreement is expected to be beneficial for Fennec's financial position and long-term growth.

Positives

• The 40 million upfront payment significantly strengthens Fennec's financial position.
• Potential milestone payments of up to 210 million provide substantial upside for Fennec.
• Tiered royalties on net sales offer a long-term revenue stream for Fennec.
• Partnering with Norgine, a leading European specialist pharmaceutical company, provides access to established commercial infrastructure and expertise.
• The agreement covers key international markets, expanding the reach of PEDMARQSI.

Negatives

• Royalty payments are subject to reduction if generic versions of PEDMARQSI become available, which could impact long-term revenue.
• The agreement's success is dependent on Norgine's ability to effectively commercialize PEDMARQSI in the licensed territories.
• Fennec is reliant on Norgine for sales and marketing in the licensed territories.

Risks

• The introduction of generic or competing products could significantly reduce royalty payments.
• Norgine's commercialization efforts may not meet expectations, impacting Fennec's revenue.
• Regulatory approvals in Switzerland, Australia, and New Zealand are not guaranteed.
• The agreement's success is subject to market conditions and competitive pressures.
• There is a risk of delays in achieving regulatory and commercial milestones.

Future Outlook

The agreement positions Fennec to benefit from the commercialization of PEDMARQSI in key international markets, with potential for significant revenue generation through milestone payments and royalties. Norgine will be responsible for all commercialization activities in the licensed territories and will hold all marketing authorizations in the licensed territories. Approval in Switzerland, Australia and New Zealand will also be pursued.

Management Comments

• Rosty Raykov, CEO of Fennec Pharmaceuticals, stated that the partnership is an important step in expanding PEDMARQSI to patients globally and that the terms provided many important benefits, including an upfront payment, attractive economic terms and an experienced partner.
• Chris Bath, CEO of Norgine, expressed excitement about bringing PEDMARQSI to pediatric patients in Europe and ANZ and establishing it as the standard of care.

Industry Context

This agreement reflects a trend in the pharmaceutical industry where companies partner to leverage each other's strengths, with Fennec focusing on product development and Norgine on commercialization. It also highlights the growing importance of addressing unmet medical needs in pediatric populations.

Comparison to Industry Standards

• The upfront payment of 40 million is a significant amount for a licensing deal of this nature, indicating the perceived value of PEDMARQSI.
• The potential for 210 million in milestone payments is also substantial, aligning with industry norms for successful drug commercialization.
• Tiered royalties in the mid-teen to mid-twenty percent range are competitive and reflect the potential market for PEDMARQSI.
• The agreement's structure, with an exclusive license and shared responsibilities, is a common model in the pharmaceutical industry.
• The long-term nature of the agreement, with potential for automatic renewals, is typical for pharmaceutical licensing deals.

Stakeholder Impact

• Shareholders will benefit from the upfront payment and potential future revenue streams.
• Employees of Fennec may see increased job security and growth opportunities.
• Patients in the licensed territories will gain access to PEDMARQSI, a treatment for cisplatin-induced hearing loss.
• Norgine will expand its product portfolio and market presence.
• Suppliers of Fennec may see increased demand for their products.

Next Steps

• Norgine will take over commercialization activities in the licensed territories.
• Norgine will pursue regulatory approvals in Switzerland, Australia, and New Zealand.
• Fennec and Norgine will collaborate on the transfer of marketing authorizations.
• The companies will establish a joint steering committee to oversee the partnership.
• Fennec will continue to supply the product to Norgine.

Key Dates

Keywords

PEDMARQSI, Fennec Pharmaceuticals, Norgine, Licensing Agreement, Commercialization, Ototoxicity, Cisplatin, Europe, Australia, New Zealand, Milestone Payments, Royalties, Pharmaceuticals